Direct Acting Antivirals For Hepatitis C
Viral hepatitis c, for short, is a kind of caused by hepatitis c virus (HCV) infection in viral hepatitis, main transmission through blood transfusion, acupuncture, drugs, etc, according to the world health organization, the world of HCV infection rate is about 3%, an estimated 180 million people are infected with HCV, every year around 35000 new cases of hepatitis c patients. Hepatitis c is a global epidemic, can lead to chronic inflammation of the liver necrosis and fibrosis, some patients may develop liver cirrhosis and hepatocellular carcinoma (HCC). Over the next 20 years mortality associated with HCV infection (liver failure and hepatocellular carcinoma (HCC) deaths) will continue to increase, great harm to patients health and life, has become a serious social and public health problems.
Harvoni：For 1, 4, 6, type c without interferon, it was the first to cure hepatitis c without the need for joint interferon hepatitis c drugs. For hepatitis c type 1 patients has a high cure rate of 95%, and side effects are very small, and also had a shorter treatment time.
Sofosbuvir：The drug is first without joint interferon can be safe and effective drug for the treatment of certain types of hepatitis c. Clinical trials confirm for type 1 and 4 c, the drug combination of polyethylene glycol (peg) interferon and ribavirin overall sustained virological response (SVR) is as high as 90%; In view of the type 2 c, the drug plus ribavirin SVR is 89% - 95%; In view of the 3 c, the drug plus ribavirin SVR is 61% - 63%.